Skip to main content
padlock icon - secure page this page is secure

Open Access The Role of Toll-Like Receptors in Oncotherapy

Download Article:
 Download
(HTML 96.1 kb)
 
or
 Download
(PDF 192.3 kb)
 
Toll-like receptors (TLRs) are associated with tumor growth and immunosuppression, as well as apoptosis and immune system activation. TLRs can activate apoptosis and innate and adaptive immunity pathways, which can be pharmacologically targeted for the development of anticancer oncotherapies. Several studies and clinical trials indicate that TLR agonists are promising adjuvants or elements of novel therapies, particularly when used in conjunction with chemotherapy or radiotherapy. An increasing number of studies suggest that the activation of TLRs in various cancer types is related to oncotherapy; however, before this finding can be applied to clinical practice, additional studies are required. Research suggests that TLR agonists may have potential applications in cancer therapy; nevertheless, because TLR signaling can also promote tumorigenesis, a critical and comprehensive evaluation of TLR action is warranted. This review focuses on recent studies that have assessed the strengths and weaknesses of utilizing TLR agonists as potential anticancer agents.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Combination treatment; Oncotherapy; Toll-like receptors (TLRs)

Document Type: Research Article

Affiliations: 1: Department of Gastroenterology, Second Affiliated Hospital of Harbin Medical University, Harbin, P.R. China 2: Department of Critical Care Medicine, Third Affiliated Hospital of Harbin Medical University, Harbin, P.R. China 3: Department of Pain, Second Affiliated Hospital of Harbin Medical University, Harbin, P.R. China

Publication date: August 8, 2019

This article was made available online on March 25, 2019 as a Fast Track article with title: "The Role of Toll-like Receptors in Oncotherapy".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more